Kronos downgraded by Piper Sandler with a new price target
$KRON
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $6.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 11/14/2024 | Buy → Hold | TD Cowen | |
| 9/14/2022 | $12.00 | Buy | Berenberg |
| 2/28/2022 | $50.00 → $30.00 | Overweight | Piper Sandler |
| 11/10/2021 | $35.00 → $36.00 | Buy | HC Wainwright & Co. |
| 10/20/2021 | Outperform | Cowen | |
| 6/24/2021 | $35.00 | Buy | HC Wainwright & Co. |
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
S-8 POS - Kronos Bio, Inc. (0001741830) (Filer)
S-8 POS - Kronos Bio, Inc. (0001741830) (Filer)
S-8 POS - Kronos Bio, Inc. (0001741830) (Filer)